Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury

Tolcapone and entacapone are catechol‐O‐methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, DM, Yang, Y, Watkins, PB, Howell, BA, Siler, SQ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728295/
https://www.ncbi.nlm.nih.gov/pubmed/26844013
http://dx.doi.org/10.1002/psp4.12053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728295/
https://www.ncbi.nlm.nih.gov/pubmed/26844013
http://dx.doi.org/10.1002/psp4.12053

Ejemplares similares